CA2396739A1 - Compositions for treating abnormalities in glomerular filtration, patent ductus arteriosus and osteoporosis - Google Patents

Compositions for treating abnormalities in glomerular filtration, patent ductus arteriosus and osteoporosis Download PDF

Info

Publication number
CA2396739A1
CA2396739A1 CA002396739A CA2396739A CA2396739A1 CA 2396739 A1 CA2396739 A1 CA 2396739A1 CA 002396739 A CA002396739 A CA 002396739A CA 2396739 A CA2396739 A CA 2396739A CA 2396739 A1 CA2396739 A1 CA 2396739A1
Authority
CA
Canada
Prior art keywords
group
patient
compound
amino acids
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002396739A
Other languages
English (en)
French (fr)
Inventor
Krishna G. Peri
Sylvain Chemtob
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre Hospitalier Universitaire Saint Justine
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2396739A1 publication Critical patent/CA2396739A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pipe Accessories (AREA)
  • Flanged Joints, Insulating Joints, And Other Joints (AREA)
  • Joints With Sleeves (AREA)
  • Water Treatment By Sorption (AREA)
  • Water Treatment By Electricity Or Magnetism (AREA)
CA002396739A 1999-12-06 2000-12-06 Compositions for treating abnormalities in glomerular filtration, patent ductus arteriosus and osteoporosis Abandoned CA2396739A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45548399A 1999-12-06 1999-12-06
US09/455,483 1999-12-06
PCT/CA2000/001445 WO2001042281A1 (en) 1999-12-06 2000-12-06 Compositions for treating abnormalities in glomerular filtration, patent ductus arteriosus and osteoporosis

Publications (1)

Publication Number Publication Date
CA2396739A1 true CA2396739A1 (en) 2001-06-14

Family

ID=23808998

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002396739A Abandoned CA2396739A1 (en) 1999-12-06 2000-12-06 Compositions for treating abnormalities in glomerular filtration, patent ductus arteriosus and osteoporosis

Country Status (12)

Country Link
US (1) US7442763B2 (enExample)
EP (1) EP1244693B1 (enExample)
JP (1) JP2003516417A (enExample)
AT (1) ATE298346T1 (enExample)
AU (1) AU784630B2 (enExample)
CA (1) CA2396739A1 (enExample)
DE (1) DE60020997T2 (enExample)
ES (1) ES2246915T3 (enExample)
MX (1) MXPA02005626A (enExample)
NZ (1) NZ520762A (enExample)
WO (1) WO2001042281A1 (enExample)
ZA (1) ZA200205795B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040235749A1 (en) * 1999-09-15 2004-11-25 Sylvain Chemtob G-protein coupled receptor antagonists
AU784630B2 (en) 1999-12-06 2006-05-18 Hopital Sainte-Justine Compositions for treating abnormalities in glomerular filtration, patent ductus arteriosus and osteoporosis
WO2003030911A1 (en) * 2001-10-08 2003-04-17 Medical Research Council Use of prostaglandin e synthase inhibitors, or ep2 or ep4 receptor antagonists, in the treatment of a pathological condition of the uterus
EP1450813B1 (en) * 2001-10-31 2007-08-29 Medical Research Council Antagonists of prostaglandin receptors ep2 and/or ep4 for the treatment of menorrhagia
US7414029B2 (en) 2002-05-23 2008-08-19 Theratechnologies, Inc. Antagonistic peptides of prostaglandin E2 receptor subtype EP4
JP2006506327A (ja) * 2002-05-23 2006-02-23 セラテクノロジーズ インコーポレイティド プロスタグランジンｅ２の受容体サブタイプｅｐ４のアンタゴニスト・ポリペプチド
EP1878741A3 (en) * 2002-05-23 2008-02-20 Theratechnologies Inc. Antagonistic peptides of prostaglandin E2 receptor subtype EP4
WO2004073589A2 (en) * 2003-02-24 2004-09-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein coupled receptor prostaglandin e2 ep4 (prostaglandin e2 ep4)
US8618054B2 (en) * 2004-05-05 2013-12-31 Valorisation-Rechereche Société en Commandite Interleukin-1 receptor antagonists, compositions, and methods of treatment
WO2013167582A1 (en) 2012-05-09 2013-11-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for prevention or treatment of chronic obstructive pulmonary disease
US12036286B2 (en) 2021-03-18 2024-07-16 Seagen Inc. Selective drug release from internalized conjugates of biologically active compounds

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9019120D0 (en) * 1990-09-01 1990-10-17 Beecham Group Plc Novel compounds
AU4855393A (en) * 1992-09-10 1994-03-29 New York University Polypeptides of g-coupled receptor proteins, and compositions and methods thereof
CA2157510A1 (en) * 1993-03-05 1994-09-15 Howard M. Grey Hla-a2.1 binding peptides and their uses
US5869281A (en) 1993-06-25 1999-02-09 Merck Frosst Canada Inc. DNA encoding prostaglandin receptor FP
US5605814A (en) * 1993-08-31 1997-02-25 Merck Frosst Canada Inc. DNA encoding human prostaglandin receptor EP2
AU685187B2 (en) * 1993-10-29 1998-01-15 Incyte Pharmaceuticals, Inc. Chimeric proteins including protease nexin-1 variants
EP0756604A1 (en) * 1994-04-22 1997-02-05 THE UNITED STATES OF AMERICA, as represented by the Secretary of the Department of Health and Human Services Melanoma antigens
US5866679A (en) * 1994-06-28 1999-02-02 Merck & Co., Inc. Peptides
WO1996006856A1 (en) * 1994-08-31 1996-03-07 Robert Webber Dopamine receptor peptides and anti-peptide antibodies
CN1160115C (zh) * 1994-12-12 2004-08-04 奥默罗斯公司 用于抑制疼痛,炎症和痉挛的冲洗液和方法
EP0870198A4 (en) 1995-01-25 2001-04-04 Cor Therapeutics Inc RECOMBINANT C140 RECEPTOR, ITS AGONISTS AND ANTAGONISTS, AND NUCLEIC ACIDS ENCODING THE RECEPTOR
US5877155A (en) * 1995-03-17 1999-03-02 The Research Foundation Of State University Of New York Mimotopes and anti-mimotopes of human platelet glycoprotein Ib/IX
US6117839A (en) * 1995-06-07 2000-09-12 Gensci Regeneration Sciences, Inc. Bone stimulating factor
AU2658897A (en) * 1996-03-21 1997-10-10 Epimmune, Inc. Hla-a2.1 binding peptides and their uses
WO1998010651A1 (en) * 1996-09-12 1998-03-19 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
US5955575A (en) * 1997-12-22 1999-09-21 Hopital Sainte-Justine Antagonists of G-protein-coupled receptor
AUPP320998A0 (en) * 1998-04-27 1998-05-21 Walter And Eliza Hall Institute Of Medical Research, The Tyrosine phosphatase IA-2 T-cell epitopes
US6984719B1 (en) * 1998-09-17 2006-01-10 Hospital Sainte-Justine Peptide antagonists of prostaglandin F2α receptor
US20040235749A1 (en) * 1999-09-15 2004-11-25 Sylvain Chemtob G-protein coupled receptor antagonists
AU784630B2 (en) 1999-12-06 2006-05-18 Hopital Sainte-Justine Compositions for treating abnormalities in glomerular filtration, patent ductus arteriosus and osteoporosis

Also Published As

Publication number Publication date
EP1244693A1 (en) 2002-10-02
US20030017988A1 (en) 2003-01-23
WO2001042281A1 (en) 2001-06-14
DE60020997D1 (de) 2005-07-28
ATE298346T1 (de) 2005-07-15
NZ520762A (en) 2005-02-25
JP2003516417A (ja) 2003-05-13
ES2246915T3 (es) 2006-03-01
AU2134001A (en) 2001-06-18
AU784630B2 (en) 2006-05-18
DE60020997T2 (de) 2006-05-24
MXPA02005626A (es) 2004-09-10
EP1244693B1 (en) 2005-06-22
US7442763B2 (en) 2008-10-28
ZA200205795B (en) 2007-01-31

Similar Documents

Publication Publication Date Title
JP5502480B2 (ja) 生物活性ペプチド及びその使用方法
JP4786047B2 (ja) ペプチド誘導体
JP2008506632A (ja) メタスチン誘導体およびその用途
CA2260767A1 (en) Fas ligand-like protein, its production and use
KR20230036156A (ko) α4β7 인테그린 티오에테르 펩티드 길항제
EP1244693B1 (en) Compositions for treating abnormalities in glomerular filtration, patent ductus arteriosus and osteoporosis
JP2010532988A (ja) 生物活性ペプチドおよびその使用方法
US20040023853A1 (en) Antagonistic peptides of prostaglandin E2 receptor subtype EP4
CA3054169C (en) Compositions and methods for improving sexual function in a male with benign prostatic hyperplasia
JP2006506327A5 (enExample)
US9155795B2 (en) CXCR4 receptor compounds
AU701677B2 (en) Recombinant C140 receptor and its agonists and antagonists
WO1997011091A1 (fr) Nouveaux composes peptidiques et leurs compositions medicinales
CA2342960C (en) G protein-coupled receptor antagonists
JP2003516417A5 (enExample)
JP2008013436A (ja) 血管形成促進剤
US7414029B2 (en) Antagonistic peptides of prostaglandin E2 receptor subtype EP4
US20250197838A1 (en) Urokinase-type plasminogen activator receptor binding peptides and methods of use
JPH10271997A (ja) 新規Ｆａｓリガンド様タンパク質およびそのＤＮＡ
WO2020000063A1 (en) Rheumatoid arthritis treatment
EP1878741A2 (en) Antagonistic peptides of prostaglandin E2 receptor subtype EP4
JP2000159795A (ja) ペプチド誘導体
JP2002355077A (ja) カスパーゼ３阻害剤
JPH06293660A (ja) 腫瘍壊死因子阻害活性を有する新規ペプチド

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued